RE:RE:RE:RE:RE:So what if I told you The math works also from 20 to 30 !!!
I know that I am almodt alone in my camp pushing and believing that we are still in the midst of launching the 2 drugs which has a terrible execution upon the original launch and when Paul theLauncher in Chief joined the pandemic put a halt in the relaunch for two years So we are now at the start of the re launch and I still feel that the market undervalues the commercial potential by ar least 2.50-3.00 per share ...
I know some here consider this chicken feed compared to billions of dollar mkt potential of the Sort 1 Platform but nuts and bolts are what keeps things together while waiting for the promised Land
qwerty22 wrote:
If one Q they enrolled two people and the next Q they enrolled 3 people then that would be an increase of the enrolment rate of 50% Q over Q.
SPCEO1 wrote: Frankly, what Paul was saying about huge increases in patient counts, or something like that, must be poppycock in some manner as it sounds great but it is not translating into sales yet. I thought we might get a popsitive surprise in Egrifta sales in Q2 but Bloomberg led us astray again. All that being said, you might find this article of interest:
https://editorialge.com/tesamorelin-injection/
palinc2000 wrote: The growth potential of the sales of Egtifta and Trogarzo is what makes THTX a much less risky investment than im other biotechs...Paul kept referring to the 6 periods .....I think he means 6 quarters .... since his tenure???? Anyway he mentioned enrollment (?)in Egrifta up 44% and he said something like it is very uncommon for a drug to have been on the market for so long to have over 20% growth rate.... He even mentioned that there is a good chance of exceeding the sales guidance
My confidence in sales exceeding 100 million next year increases my patience for other events to happen
qwerty22 wrote: If you timed how long they spent talking about each part of the business it wouldn't surprise me if the most time was spent on Egrifta.